^
Association details:
| Biomarker: | PREX2 M627V |
|---|---|
| Cancer: | Gastric Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors
Excerpt:
...mutation status of TGFBR2, RHOA, and PREX2 influenced the PFS of immunotherapy...PREX2 p.M627V, p.W519G, p.R1567Q mutations had been identified and the median PFS of patients with PREX2wt and PREX2mt were 5.0 months (95%CI,2.0–8.0 months) and 2.4 months (95%CI, 0.5–4.3 months; p = 0.037), respectively.
DOI:
10.1186/s12943-020-01274-7
